Pharma Industrial India Magazine - July - August 2024

Abbott Signs Global Partnership with Medtronic for Insulin Delivery Devices Biocon Biologics Signs License Deal with Janssen for Bmab 1200 Abbott has inked a global partnership with Medtronic to collaborate on an in- tegrated continuous glucose monitoring (CGM) system based on Abbott’s most advanced, FreeStyle Libre technology that will connect with Medtronic’s auto- mated insulin delivery (AID) and smart insulin pen systems. The integration of Abbott’s CGM sensor with Medtronic’s AID algorithms will en- able automatic adjustments of insulin to keep glucose in range. The CGM sen- sor, designed to work exclusively with Medtronic devices, will be developed by Abbott and sold by Medtronic. AID systems improve health outcomes while reducing the burden of constant decision-making for people with diabe- tes who use intensive insulin as part of their overall therapy. AID systems can benefit people with both Type 1 and Type 2 diabetes who require multiple daily injections of rapid-acting insulin, currently estimated at more than 11 mil - lion people globally. “This partnership pairs two global lead- ers in glucose sensing technology and insulin delivery,” said Jared Watkin, ex- ecutive vice president of Abbott’s dia- betes care business. “Libre technology has set the standard for accurate, ac- cessible, easy-to-use and reliable con- tinuous glucose monitoring. Connecting this CGM built for Medtronic’s insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living.” “Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world,” said Que Dallara, Executive Vice President and President, Medtronic Diabetes. “We’re committed to simplifying diabe- tes management and making the tran- sition to automated technology much more seamless for those who wish to achieve more with their diabetes care,” Dallara added. This collaboration with Medtronic is the latest in a series of Abbott partnerships aimed at improving and streamlining di- abetes care, giving people more choic- es to confidently administer their insu - lin. Abbott’s Libre single-analyte CGM technology is currently available and integrated with AID offerings from other insulin delivery companies. Biocon Biologics has signed a settle- ment and license agreement with Jans- sen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collec- tively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara, in Eu- rope, the United Kingdom (UK), Cana- da, and Japan. Under the terms of this settlement agreement, Biocon Biologics has re- solved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan. Regulatory filings in these markets are currently un - der review. Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no lat - er than February 22, 2025, once ap - proved by the US FDA. The US FDA has accepted the company’s Biologics License Application (BLA) for Bmab 1200 (bUstekinumab) for review under the 351(k) pathways. Shreehas Tambe, CEO and Managing Director, Biocon Biologics Ltd., said, “This settlement agreement is a tes- tament to our proven track record of science and innovation and is another key milestone in our journey to bring our biosimilar Bmab 1200 (bUstekinumab) to global markets. Bmab 1200 will sig - nificantly strengthen our immunology franchise, enabling us to offer an afford- able and effective treatment option for patients impacted by autoimmune dis- eases.” NEWS PHARMA INDUSTRIALINDIA · JUL-AUG 24 10